内部人交易记录
其他基于 1 个已确定 T+90 收益的买入信号。收益基准：公布次日的收盘价。
Browse the detailed record of transactions filed by Jin David. Officer active across 3 companies, notably Fortress Biotech, Inc.. Aggregated, 14 disclosures have been recorded. Breakdown: 4 buys · 0 sell. Total volume traded: €34k. Activity tracked since 26 October 2022. The latest transaction was filed on 1 April 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Jin David
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报14 总计
400,000 股Common Stock, par value $0.001SEC:0001930732-26-000003:0
2,967 股@ US$2.17610.7% 占其流量Common Stock, par value $0.001SEC:0001930732-26-000002:0
247 股@ US$0.962100.0% 占其流量COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-25-125227:0
2,711 股@ US$1.3095.5% 占其流量Common Stock, par value $0.001SEC:0001930732-25-000004:0
5,000 股@ US$1.215512.1% 占其流量Common Stock, par value $0.001SEC:0001415889-25-009369:0
1,000,000 股0Common Stock, par value $0.001SEC:0001415889-24-030071:0
2,625 股@ US$1.22836.3% 占其流量Common Stock, par value $0.001SEC:0001415889-24-024183:0
65,000 股0COMMON STOCK, PAR VALUE $0.0001SEC:0001104659-24-102834:0
500 股@ US$7.507.5% 占其流量SERIES A CUMULATIVE PERPETUAL PREFERRED STOCKSEC:0001104659-24-079409:0
2,352 股@ US$1.708.0% 占其流量COMMON STOCK, PAR VALUE $0.001SEC:0001104659-24-042504:0
140,000 股0COMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-128788:0
35,928 股@ US$0.83560.2% 占其流量COMMON STOCK, PAR VALUE $0.001SEC:0001104659-23-021541:0
5,000 股@ US$0.565.8% 占其流量COMMON STOCK, PAR VALUE $0.001SEC:0001104659-22-124100:0
1,350,000 股0COMMON STOCK, PAR VALUE $0.001SEC:0001104659-22-112522:0
About Jin David
Jin David has 14 filings in total. Among the sampled recent filings from 2022-10-28 to 2026-06-24, the reported buy volume is EUR 34302 and the reported sell volume is EUR 0, with Attribution as the dominant transaction nature. He is Chief Financial Officer at Fortress Biotech, Inc., Director at Mustang Bio, INC., and Interim PFO and COO at Avenue Therapeutics, INC.